These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22304357)

  • 1. [Comparative evaluation of antiplatelet efectiveness drugs of original and reproduced enteric forms of acetylsalicylic acid (clinical study ICAR))].
    Martsevich SIu; Tolpygina SN; Lukina IuV; Voronina VP; Kiseleva NV; Boĭchenko ES; Dubinskaia RÉ; Khoseva EN
    Kardiologiia; 2012; 52(1):74-82. PubMed ID: 22304357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
    Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
    Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
    Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
    Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
    J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?
    Sibbing D; Gross L; Aradi D
    Thromb Haemost; 2016 Jan; 115(1):3-6. PubMed ID: 26334227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
    Kardassis D; Egnell AC; Åstrand M; Daniels SJ; Whatling C; Fjellström O; Gabrielsen A
    J Am Heart Assoc; 2024 Jun; 13(11):e033985. PubMed ID: 38804212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
    Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
    J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
    Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
    Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
    J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption and efficacy of acetylsalicylic acid in patients with short bowel syndrome.
    Faye E; Drouet L; De Raucourt E; Green A; Bal-Dit-Sollier C; Boudaoud L; Corcos O; Bergmann JF; Joly F; Lloret-Linares C
    Ann Pharmacother; 2014 Jun; 48(6):705-10. PubMed ID: 24667978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].
    Mesitskaia DF; Nikitina IuM; Lomakin OV; Shchekochikhin DIu; Kopylov FIu
    Ter Arkh; 2014; 86(9):77-82. PubMed ID: 25518510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of speed of an anti-platelet effect after two different doses of acetylsalicylic acid by flocculation].
    Malý M; Vojácek J; Hadacová I; Mates M; Hájek P; Durdil V
    Vnitr Lek; 2004 Jun; 50(6):428-33. PubMed ID: 15346635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin in coronary artery disease: an appraisal of functions and limitations.
    Würtz M
    Dan Med J; 2015 Apr; 62(4):B5011. PubMed ID: 25872543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
    Hong Y; Gengo FM; Rainka MM; Bates VE; Mager DE
    Clin Pharmacokinet; 2008; 47(2):129-37. PubMed ID: 18193919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
    Bagoly Z; Homoródi N; Kovács EG; Sarkady F; Csiba L; Édes I; Muszbek L
    Platelets; 2016; 27(1):59-65. PubMed ID: 26083485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally given gastroprotective capsaicin does not modify aspirin-induced platelet aggregation in healthy male volunteers (human phase I examination).
    Sandor B; Papp J; Mozsik G; Szolcsanyi J; Keszthelyi Z; Juricskay I; Toth K; Habon T
    Acta Physiol Hung; 2014 Dec; 101(4):429-37. PubMed ID: 25532954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.